This week in techniques



Licensing status

Publication and contact information

Drug platforms

Cross-reactive anti-HIV antibody to guide vaccine epitope development

Structural and evolutionary analysis of a new cross-reactive HIV antibody could be used to design vaccines to help prevent the disease. A time-course analysis of blood samples taken from a newly infected patient with HIV tracked the evolution of a new cross-reactive anti-HIV Env antibody that neutralized 55% of viral isolates in vitro. The antibody showed less somatic mutation than previously identified broadly neutralizing antibodies, and its germline B cell receptor precursor bound HIV Env with low nanomolar affinity. Next steps could include using HIV Env variants from this viral isolate to guide the design of vaccine epitopes.

SciBX 6(14); doi:10.1038/scibx.2013.352
Published online April 11, 2013

Patent applications filed; licensing status unavailable

Liao, H.-X. et al. Nature; published online April 3, 2013;
Contact: Hua-Xin Liao, Duke University, Durham, N.C.
Contact: Barton F. Haynes, same affiliation as above